The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia

American Journal of Gastroenterology

Volumn 98, Issue 9, 2003, Pages 1952-1962

  Kearney, David J ^a   Liu, Chuan Fen ^b   Crump, Casey ^b   Brousal, Andrea ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBIOTIC AGENT; BISMUTH SALICYLATE; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; FAMOTIDINE; LANSOPRAZOLE; MAGNESIUM HYDROXIDE; METOCLOPRAMIDE; METRONIDAZOLE; NIZATIDINE; OMEPRAZOLE; RANITIDINE; SIMETHICONE; STOMACH SECRETION INHIBITOR; SUCRALFATE; TETRACYCLINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BARRETT ESOPHAGUS; DRUG COST; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL RUNNING COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; PEPTIC ULCER; PRIORITY JOURNAL; SELF REPORT; UNITED STATES;

EID: 0141459715     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07584.x     Document Type: Article

References (40)

1. Levin TR, Kunz K, Henke CJ, Selby JV. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997;103:520-8.
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
3. Coghlan JG, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers-a 12 month follow-up study. Lancet 1987;ii:II09-I1.
4. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
5. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93:1409-15.
6. Sonnenberg A, Schwartz JS, Cutler AF, et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: Results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998;158:852-60.
7. Levin TR, Schmittdiel JA, Henning JM, et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998;93:743-7.
8. Lassen AT, Pederson FM, Bytzer P, Schaffalitzky de Muckadell OB. H. pylori "Test and treat" or prompt endoscopy for dyspeptic patients in primary care. A randomized controlled trial of two management strategies: One year follow-up. Gastroenterology 1998;114:A196.
9. Heaney A, Collins JSA, Watson RGP, et al. A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45:186-90.
10. American Gastroenterological Association Medical Position Statement. Evaluation of Dyspepsia. Gastroenterology 1998;114:579-81.
11. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: Results from 224 patients. Dig Dis Sci 1999;45:265-71.
12. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95:914-20.
13. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: Impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Therapeut 2000;14:729-35.
14. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
15. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Lancet 2000;355:1665-9.
16. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: A post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7.
17. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J 1999;318:833-7 [see comments].
18. Talley NJ, Vakil N, Ballard DE, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.
19. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1875-81.
20. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Therapeut 2000;14:45-51.
21. Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: A prospective trial. Aliment Pharmacol Therapeut 2002;16:1143-8.
22. Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Therapeut 1999;13:915-20.
23. Sharma VK, Howde CW. H. pylori (Hp), intragastric (IG) pH and esophageal acid exposure (EAE)-the GERD triangle. Gastroenterology 2001;129:A-48.
24. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial. Lancet 2001;357:1738-42.
25. O'Connor HJ. Helicobacter pylori and gastro-esophageal reflux disease-clinical implications and management. Aliment Pharmacol Therapeut 1999;I3:I17-27 (review article).
26. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
27. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
28. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576-8.
29. Verma S, Giaffer MH. Helicobacter pylori eradication in patients on long-term H2 receptor antagonists. Economic and symptomatic benefits. A large prospective study in primary care. Helicobacter 2002;7:91-8.
30. Khan Z, Nair P, O'Shea C, et al. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol 2002;37:144-7.
31. Sontag SJ, O'Connell S, Schnell T, et al. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/ amoxicillin/clarithromycin. Am J Gastroenterol 2001;96:1390-5.
32. Fendrick AM, McCort JT, Chernew ME, et al. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: Clinical and economic effects. Am J Gastroenterol 1997;92:2017-24.
33. Joosen EA, Reininga JH, Manders JM, et al. Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: A prospective intervention study in general practice. Eur J Gastroenterol Hepatol 2000;12:319-25.
34. McColl KE, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
35. Tan ACITL, Den Hartog GD, Mulder CJJ. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. Aliment Pharmacol Ther 1999;13:1519-22.
36. Stevens R, Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gastroenterology 2001;120:A-50.
37. Morris JA, Craig CF, Morran C, et al. ACID 1 study: Results of a randomized controlled trial of H. pylori eradication in patients on maintenance acid suppression in the community. Gastroenterology 2001;120:A-235.
38. Stuart RC, Craig CF, Morran C, et al. Helicobacter pylori eradication reduces prescribing costs in dyspepsia irrespective of underlying diagnosis. Gastroenterology 2001;120: A-236.
39. Chiba N, Veldhuyzen van Zanten S, Grace EM, et al. The cost-effectiveness of an H. pylori test and treat approach in primary care uninvestigated dyspepsia patients. Gastroenterology 2001;120:A-89.
40. Brennan MS, Vakil N, Ofman JJ. Dyspepsia management in primary care: A reappraisal of competing strategies. Gastroenterology 2001;120:A-50.